MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera | MicrobiomeTrials← Back to trialsNCT04116502
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2019-10-25Est. Completion: 2028-10-31
Enrollment target: 586 participants Locations- Aberdeen Royal Infirmary, Aberdeen, United Kingdom
- Royal United Hospital, Bath, United Kingdom
- Belfast City Hospital, Belfast, United Kingdom
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
- Blackpool Victoria Hospital, Blackpool, United Kingdom
- Glan Clwyd Hospital, Bodelwyddan, United Kingdom
- Royal Bournemouth Hospital, Bournemouth, United Kingdom
- Southmead Hospital, Bristol, United Kingdom
- Addenbrooke's Hospital, Cambridge, United Kingdom
- Kent and Canterbury Hospital, Canterbury, United Kingdom
- University Hospital of Wales, Cardiff, United Kingdom
- St Richard's Hospital, Chichester, United Kingdom
- Colchester Hospital, Colchester, United Kingdom
- Castle Hill Hospital, Cottingham, United Kingdom
- University Hospital, Coventry, United Kingdom
- Russells Hall Hospital, Dudley, United Kingdom
- Western General Hospital, Edinburgh, United Kingdom
- Royal Devon and Exeter Hospital, Exeter, United Kingdom
Other microbiome trials you might be interested in
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patient…
Salt Lake City, United StatesCompleted Aug 16, 2023
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to impr…
Gloucestershire Royal Hospital, Gloucester, United KingdomCalderdale Royal Hospital, Halifax, United KingdomHuddersfield Royal Infirmary, Huddersfield, United KingdomRaigmore Hospital, Inverness, United KingdomIpswich Hospital, Ipswich, United KingdomKettering General Hospital, Kettering, United KingdomSt James's University Hospital, Leeds, United KingdomLeicester Royal Infirmary, Leicester, United KingdomSt John's Hospital, Livingston, United KingdomUniversity College Hospital, London, United KingdomGuy's Hospital, London, United KingdomSt George's Hospital, London, United KingdomWythenshawe Hospital, Manchester, United KingdomArrowe Park Hospital, Metropolitan Borough of Wirral, United KingdomThe James Cook University Hospital, Middlesbrough, United KingdomFreeman Hospital, Newcastle upon Tyne, United KingdomRoyal Gwent Hospital, Newport, United KingdomNorth Tyneside General Hospital, North Shields, United KingdomNorthampton General Hospital, Northampton, United KingdomNorfolk and Norwich University Hospital, Norwich, United KingdomNottingham City Hospital, Nottingham, United KingdomGeorge Eliot Hospital, Nuneaton, United KingdomChurchill Hospital, Oxford, United KingdomDerriford Hospital, Plymouth, United KingdomRoyal Berkshire Hospital, Reading, United KingdomHalton Hospital, Runcorn, United KingdomRoyal Hallamshire Hospital, Sheffield, United KingdomWexham Park Hospital, Slough, United KingdomSouthampton General Hospital, Southampton, United KingdomRoyal Stoke University Hospital, Stoke-on-Trent, United KingdomSunderland Royal Hospital, Sunderland, United KingdomGood Hope Hospital, Sutton Coldfield, United KingdomRoyal Cornwall Hospital, Truro, United KingdomWarwick Hospital, Warwick, United KingdomNew Cross Hospital, Wolverhampton, United KingdomWorthing Hospital, Worthing, United KingdomYork Hospital, York, United KingdomDenver, United States
Est. completion May 17, 2028